Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone203-535-1456
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$14.32 million
Profitability
Miscellaneous
Employees83
Next Earnings Date11/4/2019 (Estimated)
OptionableNot Optionable
Arvinas (NASDAQ:ARVN) Frequently Asked Questions
What is Arvinas' stock symbol?
Arvinas trades on the NASDAQ under the ticker symbol "ARVN."
How were Arvinas' earnings last quarter?
Arvinas Inc (NASDAQ:ARVN) released its earnings results on Monday, August, 5th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.15. The business had revenue of $4.02 million for the quarter, compared to analyst estimates of $4 million. Arvinas had a negative return on equity of 239.20% and a negative net margin of 411.20%. View Arvinas' Earnings History.
When is Arvinas' next earnings date?
What price target have analysts set for ARVN?
6 equities research analysts have issued 1 year price targets for Arvinas' stock. Their predictions range from $17.00 to $42.00. On average, they expect Arvinas' stock price to reach $29.40 in the next twelve months. This suggests a possible upside of 20.0% from the stock's current price. View Analyst Price Targets for Arvinas.
What is the consensus analysts' recommendation for Arvinas?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arvinas.
Has Arvinas been receiving favorable news coverage?
News stories about ARVN stock have trended somewhat negative this week, according to InfoTrie. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arvinas earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Arvinas.
Who are some of Arvinas' key competitors?
Some companies that are related to Arvinas include Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS), Reata Pharmaceuticals (RETA), HUTCHISON CHINA/S (HCM), Genmab A/S (GMAB), Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), PTC Therapeutics (PTCT) and Intercept Pharmaceuticals (ICPT).
What other stocks do shareholders of Arvinas own?
Who are Arvinas' key executives?
Arvinas' management team includes the folowing people:
- Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 59)
- Mr. Sean A. Cassidy, CFO & Treasurer (Age 49)
- Dr. Ian Taylor, Chief Scientific Officer (Age 56)
- Dr. Craig M. Crews, Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
- Dr. Andrew Crew, Chief Technology Officer (Age 54)
When did Arvinas IPO?
(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.
Who are Arvinas' major shareholders?
Arvinas' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.08%), Point72 Asset Management L.P. (2.04%), Vanguard Group Inc. (1.62%), Bank of America Corp DE (0.69%), Nuveen Asset Management LLC (0.65%) and Northern Trust Corp (0.32%). Company insiders that own Arvinas stock include Bradley Albert Margus, Ian Taylor, James E Flynn, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am. View Institutional Ownership Trends for Arvinas.
Which institutional investors are selling Arvinas stock?
ARVN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. Company insiders that have sold Arvinas company stock in the last year include Sean A Cassidy and Ventures Iii LP 5Am. View Insider Buying and Selling for Arvinas.
Which institutional investors are buying Arvinas stock?
ARVN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., Bank of America Corp DE, Nuveen Asset Management LLC, Vanguard Group Inc., Bank of New York Mellon Corp, Price T Rowe Associates Inc. MD and Charles Schwab Investment Management Inc.. Company insiders that have bought Arvinas stock in the last two years include Bradley Albert Margus, Ian Taylor, James E Flynn, Sean A Cassidy and Timothy M Shannon. View Insider Buying and Selling for Arvinas.
How do I buy shares of Arvinas?
Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Arvinas' stock price today?
One share of ARVN stock can currently be purchased for approximately $24.49.
How big of a company is Arvinas?
Arvinas has a market capitalization of $825.80 million and generates $14.32 million in revenue each year. The company earns $-41,480,000.00 in net income (profit) each year or ($25.45) on an earnings per share basis. Arvinas employs 83 workers across the globe.View Additional Information About Arvinas.
What is Arvinas' official website?
How can I contact Arvinas?
Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]
MarketBeat Community Rating for Arvinas (NASDAQ ARVN)
MarketBeat's community ratings are surveys of what our community members think about Arvinas and other stocks. Vote "Outperform" if you believe ARVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
